New findings from a pivotal phase 3 registrational study conducted by SELLAS Life Sciences Group demonstrated that a peptide vaccine, discovered at Memorial Sloan Kettering Cancer Center (MSK), met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice of best available treatment for patients with acute myeloid leukemia (AML) whose cancer had returned after treatment and who had achieved another remission.